NMN vs NAD+: precursor and coenzyme, explained

Prepared by: Research Desk. Sources are linked for verification.

Product labels often use "NMN" and "NAD+" as if they were two versions of the same thing. They aren't. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell. NMN (nicotinamide mononucleotide) is one of the molecules cells use to make it. The confusion is understandable, because NMN is only one enzymatic step away from NAD+. But that single step involves specific enzymes, specific cell compartments and open questions about transport, and those details matter when reading any study.

This explainer covers the chemistry of each molecule, the reaction that links them, what human research has measured, and where the evidence stops. For the wider picture of every precursor, see our NAD+ guide.

The short answer

• NAD+ is the working coenzyme. It carries electrons in energy metabolism and is consumed as a substrate by enzymes such as sirtuins, PARPs and CD38 [1][2].

• NMN is a precursor. Inside cells, enzymes called NMNATs join NMN to part of an ATP molecule to form NAD+ [1].

• Structurally, NAD+ is a dinucleotide: two nucleotides joined through their phosphate groups. One of those nucleotides is, in effect, NMN. The other is adenosine monophosphate (AMP) [1].

So NMN is a building block of NAD+, and the question "NMN vs NAD+" is really a question about a raw material versus a finished product.

The chemistry side by side

Sources for the pathway steps: reviews of NAD+ metabolism [1][3][4].

How cells turn NMN into NAD+

Cells can make NAD+ in several ways. The amino acid tryptophan feeds a "de novo" route, and nicotinic acid feeds another. In most mammalian tissues, however, the dominant source is the salvage pathway, which recycles nicotinamide released when enzymes consume NAD+ [1][4].

The salvage pathway has two key steps:

1. Nicotinamide → NMN. The enzyme NAMPT (nicotinamide phosphoribosyltransferase) attaches a phosphoribose group to nicotinamide, producing NMN. Reviews describe NAMPT as the rate-limiting step of this route, which is a large part of why NMN attracted research interest: supplying NMN directly would, in principle, bypass that bottleneck [1][3].

2. NMN → NAD+. NMNAT enzymes combine NMN with the AMP portion of ATP. Mammals have three NMNAT forms with different locations: the nucleus, the Golgi apparatus and the mitochondria [1].

Nicotinamide riboside (NR) enters the same pathway one step earlier: NRK enzymes phosphorylate NR to form NMN, which then follows step 2 [1]. That shared endpoint is why NMN and NR are often discussed together. NR's own research record is covered in a separate explainer.

The transport question

If NMN is converted to NAD+ inside cells, the obvious question is how NMN gets in. This is one of the more debated topics in the field. Reviews describe evidence that some extracellular NMN may be converted to NR at the cell surface, enter the cell as NR and then be rephosphorylated back to NMN, alongside proposals for direct NMN uptake in some tissues [2]. The relative importance of each route in humans has not been settled.

The same reviews describe NAD+ outside cells being broken down by surface enzymes, including CD38 and related ectoenzymes, into smaller molecules [2]. That is relevant to products sold as "NAD+" itself: the molecule on the label is not necessarily the molecule that reaches the inside of a cell. How much intact NAD+ from any oral or intravenous product reaches specific tissues in people is a question the cited literature does not resolve. The legal and product categories for these forms are mapped in our regulatory explainer.

Why NAD+ levels attract attention

Interest in both molecules rests on the observation that NAD+ declines with age in many tissues. Most of the early data came from animal models [3][4]. In humans, a 2012 study of human tissue samples (skin) reported age-associated changes in oxidative stress markers and NAD+ metabolism, including lower NAD+ levels in older samples [5]. Reviews link the decline to a combination of rising consumption, especially by CD38, and changes in synthesis [1][2].

That observation is the first link in a chain. Whether supplying a precursor restores NAD+ in the relevant tissues, and whether that changes any outcome in people, are separate questions that need separate evidence.

What human studies of NMN have measured

Human NMN research is relatively young. The studies below are reported as what each one measured and reported, not as evidence that NMN does anything for any individual.

• Randomized trial in prediabetic women (Science, 2021). This placebo-controlled study in a small group of women with prediabetes reported increased muscle insulin sensitivity after NMN supplementation, with NMN-related metabolites measured in muscle tissue [6]. The authors' finding was specific to muscle insulin signalling in this population.

• Multicenter trial in healthy middle-aged adults (GeroScience, 2023). A randomized, double-blind, placebo-controlled, parallel-group trial compared several daily intake levels of NMN with placebo. It measured blood NAD+ concentrations, reported their changes across groups, and assessed safety and some functional measures [7].

• Safety reviews. A 2023 review of human clinical trials summarised the safety data reported so far and noted that trials have been short and small [8]. A 2022 review set out both the research rationale for NMN and a list of safety concerns and unknowns, including long-term effects that existing trials were not designed to detect [9].

For comparison, a 2018 randomized crossover study of NR in healthy middle-aged and older adults reported that NR was well tolerated and elevated NAD+ in blood cells [10]. Raising a blood NAD+ measure is a recurring finding across precursor studies. Consistent effects on clinical outcomes are not.

Where the evidence stands

Broad reviews put these trials in context. A 2024 review of human trials exploring candidate anti-aging compounds discussed NAD+ precursors among other agents and emphasised how few outcome-level human trials exist [11]. A 2026 PRISMA-guided systematic review of preclinical and clinical NAD+ supplementation evidence found a large preclinical literature alongside a smaller and more mixed body of human data [12].

Some practical reading points follow from this:

• Blood is not tissue. Most human studies measure NAD+ or its metabolites in whole blood or blood cells. That shows a precursor was absorbed and metabolised, but not what happened in muscle, brain or liver.

• "NAD+" on a test report can mean different things. Assays may report NAD+, NADH, the total pool or a ratio, and sample handling affects results. Our NAD+ guide explains these differences.

• Population matters. A finding in prediabetic women [6] does not automatically apply to healthy adults, and vice versa [7].

• Duration matters. Trials of weeks to months cannot answer long-term safety questions [8][9].

A note on regulatory status

NMN's U.S. status has changed. Dietary supplements are regulated as a category of food, and manufacturers do not need FDA approval before marketing them [13]. A citizen petition concerning NMN's supplement status is recorded in a public docket [14]. In September 2025 FDA determined that NMN is lawful in dietary supplements, according to a law-firm analysis of the agency's response [15]. Supplement status is not an FDA finding that a product works. Details are in our regulatory explainer.

Further reading

Many readers who want to follow this topic properly find that a solid grounding in general biochemistry makes the primary literature far easier to read. Pathway diagrams, enzyme kinetics and redox chemistry are textbook material before they are research material.

When comparing biochemistry and metabolism books, these neutral criteria are worth checking: the edition date (metabolism texts revise their coverage of cofactor recycling over time), whether the salvage pathway and redox chemistry are covered in depth, whether chapters cite primary references, the author's research background, the intended level (introductory, undergraduate or graduate), and format options such as print, e-book or annotated digital editions. Price transparency across editions is also worth a look, since older editions are often much cheaper and still cover the core pathways.

How this site chooses and discloses partners is explained on our about page.

Frequently asked questions

Is NMN the same thing as NAD+?

No. NMN is a mononucleotide precursor, while NAD+ is a dinucleotide coenzyme. NMNAT enzymes combine NMN with part of an ATP molecule to form NAD+ [1].

Can a blood test show whether NMN raised NAD+?

Human trials have measured NAD+ in blood and reported changes after NMN intake [7]. A blood result reflects blood or blood cells, not necessarily other tissues, and different assays report different forms of the molecule. Results from different tests are therefore not directly comparable.

Why do researchers study NMN instead of NAD+ directly?

NMN sits after the NAMPT step, which reviews describe as rate-limiting in the salvage pathway [1][3]. Reviews also describe extracellular NAD+ being broken down by surface enzymes, so the handling of each molecule outside cells differs [2]. How much of either reaches specific human tissues remains an open research question.

Last updated: 19 October 2026.

Related on this site

• NAD Peptide Labs home

• Is NAD+ legal? NMN, NR and IV NAD+ under U.S. rules

• NAD+ explained: biochemistry, precursors, testing and human evidence

• NAD+ test buyer's guide: how at-home blood tests work and compare

• Reading an NAD+ test report: units, sample types and reference ranges

• NAD+ books: an evidence-graded reading list on sirtuins and aging

Not medical advice. This page reports published research and regulatory records for information only.

Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.

Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.